<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-5098-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        WILATE 500 IU Powder and Solvent for Solution for Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HUMAN COAGULATION FACTOR VIII,HUMAN VON WILLEBRAND FACTOR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500,500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1403.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Octapharma Pharmazeutika Produktionsges.m.b.h" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Octapharma Pharmazeutika Produktionsges.m.b.h
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 521]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Faisal Musaed El Seif Saudi Pharmaceutical Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OCTAPHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Wilate belongs to the pharmacotherapeutic group of medicines called clotting factors and contains human von Willebrand factor (VWF) and human blood coagulation factor VIII (FVIII). Together these two proteins are involved in blood clotting.<br />Von Willebrand disease<br />Wilate is used to treat and prevent bleeding in patients with von Willebrand disease (VWD), which in fact is a family of related diseases. VWD is a disturbance of blood coagulation where bleeding can go on for longer than expected. This is either due to a lack of VWF in the blood or due to VWF that does not work the way it should.<br />Haemophilia A<br />Wilate is used to treat and prevent bleeding in patients with haemophilia A. This is a condition in which bleeding can go on for longer than expected. It is due to an inborn lack of FVIII in the blood.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Wilate<br />&ndash;if you are allergic (hypersensitive) to human von Willebrand factor, blood coagulation factor VIII or any of the other ingredients of Wilate (listed in section 6).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before using Wilate<br />&ndash;Any medicine, such as Wilate, which is prepared from human blood (containing proteins) and which is injected into a vein (administered intravenously) can cause allergic reactions. Please pay attention to early signs of allergic reactions (hypersensitivity), such as hives, skin rash, tightness of the chest, wheezing, low blood pressure, or anaphylaxis (when any or all of the above symptoms develop rapidly and are intense).If these symptoms occur, stop the injection immediately and contact your doctor.</p><p>_ When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, the testing of each donation and pools of plasma for signs of virus/infections, and the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.<br />The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.<br />Parvovirus B19 infection may be serious for pregnant women (infection of the baby) and for individuals whose immune system is depressed or who have some types of anaemia (e.g. sickle cell disease or abnormal breakdown of red blood cells).<br />It is strongly recommended that every time you receive a dose of Wilate the name and the batch number of the product are recorded in order to maintain a record of the batches used.</p><p>Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/repeatedly receive human plasma-derived VWF/FVIII products.</p><p><u>Von Willebrand disease (VWD)</u><br />&ndash;Please see section 4. (Von Willebrand disease (VWD)) for side effects related to the treatment of VWD.<br /><u>Haemophilia A</u><br />&ndash;Please see section 4. (Haemophilia A) for side effects related to the treatment of haemophilia A.<br /><strong>Other medicines and Wilate</strong><br />Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Although no influences on Wilate from other medicinal products are known, please tell your doctor or pharmacist if you are taking or have recently taken any other medicines (including medicines obtained without a prescription).<br />Please do not mix Wilate with any other medicines during the injection.<br /><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br /><strong>Wilate contains sodium</strong><br />This medicinal product contains up to 2.55 mmol sodium (58.7 mg) per vial for 500 IU VWF and FVIII/vial and up to 5.1 mmol sodium (117.3 mg) per vial for 1000 IU VWF and FVIII/vial. To be taken into consideration if you are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Wilate should be injected into a vein (administered intravenously) after reconstitution with the supplied solvent. Treatment should be started under medical control.<br /><strong>Dosage</strong><br />Your doctor will advise you about your individual dosage and the frequency with which you should use Wilate. Always use Wilate exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br /><strong>If you use more Wilate than you should</strong><br />No symptoms of overdose with human VWF or FVIII have been reported. However, the recommended dosage should not be exceeded.<br /><strong>If you forget to take Wilate</strong><br />Do not take a double dosage to make up for a forgotten dosage.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Wilate can cause side effects, although not everybody gets them.<br />&ndash; Even though <strong>uncommon</strong>, hypersensitivity or allergic reactions have been observed. These may include:<br />burning and stinging at the infusion site, chills, flushing, headache, hives (urticaria), low blood pressure (hypotension), tiredness (lethargy), sickness (nausea), restlessness, increase of heart rate (tachycardia), tightness of the chest, feeling of pins and needles (tingling), vomiting, wheezing, sudden swellings in various parts of the body (angiooedema).<br />If you suffer from any of the above-mentioned symptoms, please inform your doctor.<br />You should stop using Wilate and see your doctor immediately, if you experience symptoms of angiooedema, such as:<br />&ndash;swollen face, tongue or throat (pharynx)<br />&ndash;difficulties to swallow<br />&ndash;hives and difficulties to breath<br />&ndash;On<strong> rare</strong> occasions, fever has been observed.<br />&ndash;In <strong>very rare</strong> cases, hypersensitivity may lead to a severe allergic reaction called anaphylaxis (when any or all of the above symptoms develop rapidly and are intense), which may include shock. In case of an anaphylactic shock, treatment using the current medical recommendations for shock is essential.</p><p><u>Von Willebrand disease (VWD)</u><br />&ndash; When using a FVIII-containing VWF product to treat VWD, the continued treatment may cause an excessive rise in FVIII in the blood. This may increase the risk that your blood flow will be disturbed (thrombosis).<br />If you are a patient with known clinical or laboratory risk factors, you have to be checked for early signs of thrombosis. Prevention (prophylaxis) of thrombotic events should be decided by your doctor, according to the current recommendations.<br />&ndash;Patients with VWD (especially type 3 patients) may develop inhibitors (neutralising antibodies) to VWF during the treatment with VWF. In these <strong>very rare</strong> cases inhibitors can stop Wilate working properly.<br />In case your bleeding continues, your blood has to be tested for these inhibitors.</p><p>Inhibitors may increase the risk of suffering severe allergic reactions (anaphylactic shock). If you suffer an allergic reaction, you should be tested for the presence of inhibitors.<br />Once inhibitors have been found in your blood, please contact a physician with experience in the care of patients with bleeding disorders. In patients with high amounts of inhibitors, another kind of treatment might be useful and should be considered.</p><p><br /><u>Haemophilia A</u><br />&ndash; When using FVIII products to treat patients with haemophilia A, the formation of inhibitors (neutralising antibodies) to FVIII is a known complication. In these rare cases inhibitors can stop Wilate working properly and bleeding may continue. Please contact a specialised haemophilia centre if Wilate does not stop your bleeding. Regular blood tests will be performed during treatment to test for these inhibitors.<br />Inhibitors may increase the risk of suffering severe allergic reactions (anaphylactic shock). If you suffer an allergic reaction, you should be tested for the presence of inhibitors.</p><p><br /><strong>Uncommon</strong>: may affect up to 1 in 100 people<br /><strong>Rare</strong>: may affect up to 1 in 1,000 people<br /><strong>Very rare:</strong> may affect up to 1 in 10,000 people</p><p>&nbsp;</p><p><br />There are insufficient data to recommend the use of Wilate in previously untreated patients.<br />The experience of treatment with Wilate in children less than 6 years of age is limited.<br />For information on viral safety see section 2. (Take special care with Wilate).</p><p><br />Reporting of side effects:<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Store powder and solvent vial in a refrigerator (2&deg;C &ndash; 8&deg;C).<br />Do not freeze.<br />Keep the vials in the outer carton in order to protect from light.<br />Do not use Wilate after the expiry date stated on the label.<br />Within the indicated expiry date storage for up to 6 months at room temperature (max. +25&deg;C) is permitted. The shelf-life expires after the storage at room temperature (max. +25&deg;C). The new shelf-life has to be noted on the outer carton by you.<br />The powder should be dissolved only directly before injection. Use the solution immediately after reconstitution and on one occasion only. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substances are human von Willebrand factor and human coagulation factor VIII<br /><br />- The other ingredients are sodium chloride, glycine, sucrose, sodium citrate and calcium chloride. Solvent: water for injections with 0.1% Polysorbate 80</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Freeze-dried powder: white or pale yellow powder or crumbly solid
Reconstituted solution: should be clear or slightly opalescent
Wilate is supplied as a powder and solvent for solution for injection. It comes in 2 pack sizes:
– Wilate 500, 500 IU VWF and 500 IU FVIII, powder and solvent for solution for injection, contains nominally 500 IU human von Willebrand factor and 500 IU human coagulation factor VIII per vial. The product contains approximately 100 IU/ml human von Willebrand factor and 100 IU/ml human coagulation factor VIII when reconstituted with 5 ml of Water for Injections with 0.1% Polysorbate 80 (Solvent).
– Wilate 1000, 1000 IU VWF and 1000 IU FVIII, powder and solvent for solution for injection, contains nominally 1000 IU human von Willebrand factor and 1000 IU human coagulation factor VIII per vial. The product contains approximately 100 IU/ml human von Willebrand factor and 100 IU/ml human coagulation factor VIII when reconstituted with 10 ml of Water for Injections with 0.1% Polysorbate 80 (Solvent).

Content of the package
1 vial with freeze-dried powder
1 vial with solvent
1 equipment pack with the following medical devices:
1 disposable syringe
1 transfer set (1 double-ended needle and 1 filter needle)
1 infusion set
2 alcohol swabs
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />Octapharma AG<br />Seidenstrasse 2<br />CH-8853 Lachen<br />Switzerland<br />Manufacturer<br />Octapharma Pharmazeutika<br />Produktionsges.m.b.H.<br />Oberlaaerstr. 235<br />A-1100 Vienna<br />Austria</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي وَايْلِيت إلى مجموعة من الأدوية تُسمّى عوامل التّخثُّر، ويحتوي على <strong>عامِل فون ويلبراند (</strong><strong>vWF</strong><strong>)</strong> البشري وعامِل تخثُّر الدّم البشري الثّامِن (FVIII) ويتشارك هذان البروتينان معاً في عملّيّة تخثُّر الدّم.</p><p dir="RTL"><u>مرض فون ويلبراند (</u><u>VWD</u><u>)</u></p><p dir="RTL">يُستخدم وَايْلِيت في علاج ومنع النّزيف لدى المرضى الذين يُعانون من مرض فون ويلبراند (VWD)، وهو في الحقيقة مرض وِراثي ينْشأ بِسبب خلل في عملّيّة تخثُّر الدّم حيثُ يُمكن أن يستمر النّزيف لوقت أطول مما هو مُتوقّع. سبب ذلك هو إمّا نقص عامِل فون ويلبراند (vWF) في الدّم أو أنّ عامِل فون ويلبراند (vWF)<strong> </strong>لا يعمل بالطريقة التي يُفترض أن يعمل بها. <strong>&nbsp;</strong></p><p dir="RTL"><u>مرض الهيموفيليا أ (</u><u>A</u><u>)</u></p><p dir="RTL">يُستخدم وَايْلِيت في علاج ومنع النّزيف لدى المرضى الذين يُعانون من نقص عامِل التّخثُّر الثّامِن (FVIII) المُسبِّب للاضطّراب النّزفي المُسمّى الهيموفيليا أ (A). هذه حالة مرضية يُمكن أن يستمر فيها النّزيف لوقت أطول مما هو متوقعاً. سبب ذلك هو نقص خَلقي في عامِل التخثُّر الثّامِن (FVIII) في الدّم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;<strong>لا تستخدم وَايْلِيت:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسيّة (حساسيّة مُفرِطة) تجاه عامِل فون ويلبراند (vWF)<strong> </strong>أو<strong> </strong>عامِل تخثُّر الدّم البشري الثّامِن (FVIII) أوأيّ من المُكوّنات الأخرى لـوَايْلِيت (المذكورة في الفقرة رقم 6).</p><p dir="RTL"><strong>التحذيرات والاحتياطات&nbsp; </strong></p><p dir="RTL">استشر طبيبك أو الصيدلي قبل استخدامك وَايْلِيت</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما هو الحال مع جميع الأدوية المُحضّرة من الدم البشري (التي تحتوي على بروتينات) والتي تُعْطى بالحَقْن الوريدي، فإنّ ردود فعل تحسُّسِيّة يُمكن أن تحدث مع وَايْلِيت. يُرْجى الانتباه للعلامات المُبكِّرة لردود الفعل التحسُّسِيّة أو الحساسيّة المُفرِطة والتي تشمل:</p><p dir="RTL">شرى (بُثور)، طفح جلدي، ضيق في الصدر، صفير، انخفاض ضغط الدّم؛ أو التأق (وذلك عند حدوث وتطور أيّ مِنْ أو كُلّ الأعراض المذكورة أعلاه بسرعة وبصورة شديدة).</p><p dir="RTL">في حال حُدوث هذه الأعراض يجب أن تُوقِف الحقْن حالاً واتّصِل بطبيبك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تصنيع الأدوية من الدّم البشري أو البلازما البشرية، فإنّ هناك بعض التدابير التي يجب أن تُؤْخَذ بِعين الاعتبار لمنع انتقال العدوى إلى المرضى. وهذه تشمل الاختيار الدقيق للمُتبرّعين بالدّم والبلازما لضمان استثناء الأشخاص الحاملّين للعدوى، واختبار كُلّ تبرع بالدّم وتجميعات البلازما لعلامات وجود الفيروسات /العدوى الفيروسيّة، وإدراج خطوات في عملّية مُعالجة الدّم أو البلازما لتعطيل الفيروسات أو إزالتها. وبالرغم من هذه التدابير، فإنّه لا يُمكن استبعاد إمكانية انتقال العدوى تماماً عند إعطاء الأدوية المُصنّعة من الدّم البشري أو البلازما البشرية. وينطبق هذا أيضاً على أيّ فيروسات غير معروفة أو ناشئة أو أيّ أنواع أخرى من العدوى.<br />تُعتبر هذه التّدابير فعّالة بالنسبة للفيروسات المُغلّفة مثل فيروس نقص المناعة البشري (HIV)، فيروس التهاب الكبد الوبائي ب (B)، وفيروس التهاب الكبد الوبائي ج (C)، وفيروس التهاب الكبد الوبائي أ (A) الغير مُغلّف. التدابير المُتّخذة تُعتبر ذات فعاليّة محدودة ضد الفيروسات الغير مُغلّفة مثل الفيروس الصغير (فيروس بارفو B19). العدوى بفيروس بارفو قد تكون خطيرة بالنسبة للمرأة الحامِل (تنتقل العدوى للجنين)، وكذلك للأشخاص ذوي المناعة المُنخَفِضة أو المصابين ببعض أنواع فقر الدم (مثل مرض خلِيّة الدّم المِنْجليّة أو فقر الدّم الانحلالي).</p><p dir="RTL">من المُستحسن بِشدّة أن يتمّ تسجيل اسم ورقم الدفعة للمُنتَج في كُلّ مرة تتلقّى فيها جرعة من وَايْلِيت من أجل الاحتفاظ بسجل للدفعات المُستخدمة.</p><p dir="RTL">قد يُوصيك طبيبك بأخذ تطعيم ضِدّ التهاب الكبد الوبائي أ (A) والتهاب الكبد الوبائي ب (B) إذا كنت تتلقّى مُنتجات عامِل فون ويلبراند (vWF)<strong>/</strong>عامِل تخثُّر الدّم الثّامِن (FVIII) المُشتقّة من بلازما الدّم البشري مراراً/بانتظام.</p><p dir="RTL"><u>مرض فون ويلبراند (</u><u>VWD</u><u>)</u></p><p dir="RTL">يُرجى الرجوع إلى الفقرة رقم 4: &quot;الأعراض الجانبية المُحتملة عند علاج مرض فون ويلبراند (VWD)&quot;.</p><p dir="RTL"><u>مرض الهيموفيليا أ (</u><u>A</u><u>)</u></p><p dir="RTL">يُرجى الرجوع إلى الفقرة رقم 4: &quot;الأعراض الجانبية المُحتملة عند علاج مرض الهيموفيليا أ (A)&quot;.</p><p dir="RTL"><strong>وَايْلِيت والأدوية الأخرى </strong></p><p dir="RTL">ليس هناك تأثير معروف للأدوية الأخرى على وَايْلِيت، ومع ذلك يُرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مُؤخراً، أو إذا كنت ستتناول أيّ أدوية أخرى فيما بعد بما في ذلك الأدوية التي تحصل عليها بدون وصفة طِبّية.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">استشيري طبيبك أو الصيدلي قبل استخدامك هذا الدّواء في حال كنتِ حامِلاً أو تُرضِعين طبيعيّاً، أو تعتقدين أنّك قد تكونين حامِلاً أو تخطِّطين لإنجاب طفل.</p><p dir="RTL"><strong>وَايْلِيت يحتوي على الصُّوديوم</strong></p><p dir="RTL">يحتوي هذا المُنتج على ما يصل إلى 2,55 مليمول من الصُّوديوم (ما يُعادل 58,7 مجم) في كُلّ قارورة من وَايْلِيت تحتوي على 500 وحدة دوليّة من كُلٍّ من عامِل فون ويلبراند (vWF) وعامِل التخثُّر الثّامِن (FVIII)، ويحتوي على ما يصل إلى 5,1 مليمول من الصُّوديوم (ما يُعادل 117,3 مجم) في كُلّ قارورة وَايْلِيت تحتوي على 1000 وحدة دوليّة من كُلٍّ من عامِل فون ويلبراند (vWF) وعامِل التخثُّر الثّامِن (FVIII). لذلك يجب أخذ ذلك في الاعتبار إذا كنت خاضِعاً لِنظام غذائي قليل الصُّوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يُعطَى وَايْلِيت وريديّاً (يُحْقَن في الوريد) بعد أن يتم إذابته في المُذِيب المُرفق معه.</p><p dir="RTL">استخدم فقط أدوات الحَقن المُرفقة معه. استخدام أدوات حقن أو تسريب أخرى قد يؤدّي إلى مخاطر اضافيّة وفشل العلاج.</p><p dir="RTL">يجب بدء العلاج تحت الإشراف الطِبّي.</p><p dir="RTL"><strong>الجرعة:</strong></p><p dir="RTL">سيُقوم طبيبك بتحديد مقدار وتكرار جُرعتك الشخصيّة من وَايْلِيت الذي يجب عليك استخدامه.</p><p dir="RTL">استخدم وَايْلِيت دائماً كما أخبرك طبيبك تماماً. عليك التحقُّق من طبيبك أو الصيدلي إذا كنت غير مُتأكد.</p><p dir="RTL"><strong>إذا استعملّت من وَايْلِيت أكثر ممّا يجب</strong></p><p dir="RTL">لم تُسجَّل حتّى الآن أيّ أعراض لاستخدام جرعة زائدة من عامِل فون ويلبراند (vWF) البشري أو عامِل تخثُّر الدّم الثّامِن (FVIII) البشري. ومع ذلك فإنّه لا يجب تجاوز الجرعة المُوصى بها.</p><p dir="RTL"><strong>إذا نسيت أن تأخذ </strong><strong>وَايْلِيت</strong></p><p dir="RTL">لا تأخُذ جرعة مُضاعفة للتعويض عن الجرعة المنسِيّة.</p><p dir="RTL">اسأل طبيبك أو الصيدلي إذا كان لديك المزيد من الأسئلة عن استخدام هذا الدّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يُمكن أن يُسبّب وَايْلِيت أعراضاً جانبية، مع أنها لا تحدث لدى جميع المرضى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لُوحِظ حدوث ردود فعل تحسُّسِيّة أو فرط الحساسيّة ولكن بشكل <strong>غير شائع</strong>. قد تشمل ردود الفعل هذه ما يلي:</p><p dir="RTL">الشّعور بحرقان ووخز في موضع إعطاء الحُقنة، قُشعريرة، احمِرار الوجه، طفح جلدي، صُداع، بثور (شرى)، انخفاض ضغط الدّم، تعب (شعور بالخُمول)، الشعور بالمرض (الغثيان)، هياج، ازدياد مُعدّل نبضات القلب، ضيق في الصدر، شعور بوخز كوخز الدبابيس والإبر، تقيؤ، صفير، تورّم مُفاجِئ في أجزاء مُختلِفة من الجسم (وذمة وِعائيّة).</p><p dir="RTL">ابلِغ طبيبك في حال عانَيْتَ من أيّ من هذه الأعراض المذكورة أعلاه.</p><p dir="RTL">أوقف استعمال وَايْلِيت مُباشرةً واذهب لرؤية طبيبك فوراً في حال لاحظت أحد أعراض الوذمة الوِعائيّة مثل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الوجه، اللِّسان أو الحلق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صُعوبة في البَلْع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى (بثور) وصعوبة في التنفّس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لُوحِظ حدوث حُمّى في بعض الحالات <strong>النّادِرة</strong>.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات<strong> نادرة جِدّاً</strong> قد تؤدي ردود فعل فرط الحساسيّة إلى ردود فعل شديدة تُسمّى الإِعوار أو التأق (وذلك عند حدوث وتطور أيّ مِنْ أو كُلّ الأعراض المذكورة أعلاه بسرعة وبصورة شديدة). والتي قد تشمل صدمة الحساسيّة. يجب أن تُطبّق التوصِيَات الطِّبيّة الأساسيّة في حال حدوث صدمة الحساسية.</p><p dir="RTL"><u>مرض فون ويلبراند (</u><u>VWD</u><u>)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; قد يُؤدّي استخدام مُنتج عامِل فون ويلبراند (vWF) والمُحتوِي على عامِل التّخثُّر الثّامِن (FVIII) لعلاج مرض فون ويلبراند (VWD) باستمرار إلى ارتفاع زائد لمُستوى عامِل التّخثُّر الثّامِن (FVIII) في الدّم. قد يُسبِّب ذلك اختلال في تدفق الدّم (تخثّر أو تجلّط الدّم).<br />إذا كنت من المرضى الذين لديهم عوامل الخطر السريريّة أو المَخْبريّة المعروفة، يجب التحقق من &nbsp;وجود علامات مبكرة لتخثُّر الدّم.<br />يجب أن يُحدِّد طبيبك الإجراءات اللازمة لمنع (الوقاية من) حدوث الجلطات الدّموية لديك وِفقاً للتوصِيات الطّبيّة الحاليّة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; قد ينشأ لدى المُصابين بمرض فون ويلبراند (VWD) (خاصّةً مرضى النوع الثالث) أجسام مُضادّة (مُثبِّطات) مُحيِّدة لعامِل فون ويلبراند (vWF) أثناء العلاج بعامِل فون ويلبراند (vWF). قد تُوقِف هذه المُثبِّطات في هذه الحالات <strong>النّادِرة جِدّاً</strong> فعالية عامِل فون ويلبراند (vWF).</p><p dir="RTL">لذلك في حال استمرار النّزيف لديك: فإنّه يجب إجراء فحوصات مَخْبريّة لكشف وجود هذه المُثبِّطات في دمك. قد تُسبِّب هذه المُثبِّطات زيادة خطر المُعاناة من صدمة الحساسيّة الشديدة (الإعوار أو التأق). إذا عانَيْتَ من ردود فعل تحسُّسيّة فيجب في هذه الحالة إجراء فحوصات مَخْبريّة للكشف عن وجود هذه المُثبِّطات في دمك.</p><p dir="RTL">بِمُجرّد ظهور مُثبّطات في دمك يجب عايك استشارة طبيب ذو خبرة في علاج الاضطّرابات النّزفيّة. هناك أنواع أخرى من العلاج قد تكون مفيدة ويجب اعتبارها في المرضى الذين لديهم مُستويات مُرتفِعة من المُثبِّطات.</p><p dir="RTL"><u>مرض الهيموفيليا أ (</u><u>A</u><u>)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; أحد المُضاعفات المعروفة عند استخدام مُنتجات عامِل التخثُّر الثّامِن (FVIII) لعلاج مرضى الهيموفيليا&nbsp;أ&nbsp;(A) هو نشوء أجسام مُضادّة (مُثبِّطات) مُحيِّدة لعامِل التّخثُّر الثّامِن (FVIII). في هذه الحالات <strong>النّادِرة</strong> قد تمنع هذه المُثبِّطات وَايْلِيت من العمل بفعالية ممّا يُؤدِّى إلى استمرار النزيف. يُرجى مراجعة مركز مُتخصِّص في علاج الهيموفيليا أ (A) في حال لم يتوقف النّزيف لديك بعد استخدام وَايْلِيت. سوف يتمّ إجراء فُحوصات مَخْبرية لدمك بانتظام للكشف عن هذه المُثبِّطات أثناء علاجك.</p><p dir="RTL">قد تُسبِّب هذه المُثبِّطات زيادة في خطر حدوث صدمة الحساسيّة الشديدة (الإعوار أو التأق). إذا عانَيْتَ من ردود فعل تحسُّسيّة فيجب في هذه الحالة إجراء فحوصات مَخْبريّة للكشف عن وجود هذه المُثبِّطات في دمك.</p><p dir="RTL"><strong>غير شائعة</strong>:<strong> </strong>قد تُؤثِّر على ما يصل إلى شخص واحد في كُلّ 100 شخص</p><p dir="RTL"><strong>نادرة</strong><strong>: </strong>قد تُؤثِّر على ما يصل إلى شخص واحد في كُلّ 1000 شخص</p><p dir="RTL"><strong>نادرة جداً</strong><strong>: </strong>قد تُؤثِّر على ما يصل إلى شخص واحد في كُلّ 10000 شخص</p><p dir="RTL">لا توجد بيانات كافية للتوصية باستعمال وَايْلِيت لدى المرضى الذين لم يسبق علاجهم من قبل.</p><p dir="RTL">تُوجد خبرة محدُودة لاستخدام وَايْلِيت في علاج الأطفال دون السّادسة من العمر.</p><p dir="RTL">لمعلومات عن سلامة المُنتج من الفيروسات: انظر الفقرة رقم 2 &quot;التحذيرات والاحتياطات&quot;.&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن أيّ أعراض جانبية:</strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي في حال حدوث أيّ أعراض جانبية لك. ويشمل ذلك أيّ أعراض جانبية مُحتملّة غير مُدرجة في هذه النّشْرة. يُمكنك المُساعدة في توفير مزيد من المعلومات عن سلامة هذا الدواء عند إبلاغك عن الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن أنظار ومُتناول الأطفال.</p><p dir="RTL">احفظ المسحوق والمُذِيب في الثلّاجة (في درجة حرارة 2&deg; م إلى ٨&deg; م).</p><p dir="RTL">لاتقم بتجميده.</p><p dir="RTL">احفظ القارورة في الكرتون الخارجي لحمايتها من الضوء.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصّلاحيّة المدون على الملّصق.</p><p dir="RTL">يُمكن الاحتفاظ بهذا المُنتج في درجة حرارة الغرفة (+25<sup>&deg;</sup>م كحد أقصى) لمُدّة 6 شهور ضمن تاريخ الانتهاء الأصلي للمُنتج. يجب كتابة تاريخ الصلاحية الجديد على الكرتون الخارجي للعُبوّة عند الاحتفاظ به في درجة حرارة الغرفة (+25<sup>&deg;</sup>م كحد أقصى).</p><p dir="RTL">يجب إذابة المسحوق فقط قبل حقنه مُباشرةً.</p><p dir="RTL">يجب استخدام المُنتج فورا بعد تحضيره كمحلول واستخدامه لمرة واحدة فقط.</p><p dir="RTL">لا ينبغي الّتخلّص من أيّ أدوية عن طريق مياه الصّرف الصِّحي أو الِنفايات المنزلية. اسأل الصيدلي عن كيفيّة التّخلّص من الأدوية التي لم تعد بحاجة إليها. تُساعد هذه التدابير في الحِفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مُحتويات وَايْلِيت</strong></p><p dir="RTL"><strong>مُحتويات قارورة المسحوق</strong></p><p dir="RTL"><strong>المادّة الفعّالة هي: </strong>عامِل فون ويلبراند (vWF)<strong> </strong>البشري<strong> و</strong>عامِل تخثُّر الدّم البشري الثّامِن (FVIII).</p><p dir="RTL"><strong>المواد الأخرى هي:</strong> كلوريد الصُّوديوم، جَليْسِين، سكروز، سِتْرات الصُّوديوم، وكلوريد الكالسيوم.</p><p dir="RTL"><strong>مُحتويات المُذِيب </strong></p><p dir="RTL">ماء مُعد للحقن مع 0,1% بوليسوربات 80</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل ومحتويات عبوة وَايْلِيت</strong></p><p dir="RTL"><strong>المسحوق المُجفّف بالتجميد:</strong> مسحوق أو صلب سهل التفتّت أبيض الّلون أو مائل إلى الأصفر قليلاً.</p><p dir="RTL">يجب أن يكون المحلول المُحضّر صافٍ أو غميم قليلاً.</p><p dir="RTL">يتمّ توفير وَايْلِيت كمسحوق ومُذِيب لتحضيره كمحلول للحقن. يتوفر وَايْلِيت في عبوات ذات حجمين: &nbsp;</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>وَايْلِيت 500:</strong> يتوفر كمسحوق ومُذِيب لتحضيره كمحلول للحَقن ويحتوي على <strong>500</strong> وحدة دوليّة من عامِل فون ويلبراند (vWF) البشري و<strong>500 </strong>وحدة دوليّة من عامِل تخثُّر الدّم البشري الثّامِن (FVIII) لكلّ قارورة.</p><p dir="RTL">يحتوي المُنتج تقريباً على <strong>100</strong> وحدة دوليّة/مل من عامِل فون ويلبراند (vWF) البشري و<strong>100</strong> وحدة دوليّة/مل من عامِل تخثُّر الدّم البشري الثّامِن (FVIII) عند تحضيره كمحلول بـاستخدام <strong>5 مل</strong> من الماء المُعد للحَقن مع <strong>0,1% </strong>بوليسوربات 80 (المُذِيب)</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>وَايْلِيت</strong> <strong>1000:</strong> يتوفر كمسحوق ومُذِيب لتحضيره كمحلول للحَقن ويحتوي على <strong>1000</strong>&nbsp;وحدة دوليّة من عامِل فون ويلبراند (vWF) البشري و<strong>1000</strong> وحدة دوليّة من عامِل تخثُّر الدّم البشري الثّامِن (FVIII) لكلّ قارورة.</p><p dir="RTL">يحتوي المُنتج تقريباً على <strong>100</strong> وحدة دوليّة/مل من عامِل فون ويلبراند (vWF) البشري و<strong>100 </strong>وحدة دوليّة/ملّ من عامِل تخثُّر الدّم البشري الثّامِن (FVIII) عند تحضيره كمحلول باستخدامـ <strong>10 مل</strong> من الماء المُعد للحَقن مع 0,1% بوليسوربات 80 (المُذِيب).</p><p dir="RTL"><strong>&nbsp;مُحتويات العبوة:</strong></p><p dir="RTL">قـــــــــــــــــارورة واحدة فيها المسحوق المُجفّف بالتجميد</p><p dir="RTL">قــــــــــــــــــارورة واحدة فيها المُذِيب</p><p dir="RTL">عُــــــــــــــبـــــــــــــــوّة واحدة من الأدوات الطبيّة التّالية:</p><p dir="RTL">مِــحْـقــَنـــــــــة واحدة للاستعمال مرّة واحدة</p><p dir="RTL">مجموعة واحدة لنقل المحلول (إبرة واحدة ذات رأسين، وإبره واحدة ذات فلتر)</p><p dir="RTL">مجموعة واحدة للتسريب الوريدي</p><p dir="RTL">عــــــــــدد 2 من المسحات الكحوليّة</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المالك لرخصة التّسويق والمُصنِّع</strong></p><p dir="RTL">أوكتافارما إيه جي&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;&nbsp;2 -&nbsp; شارع سيدن&nbsp;&nbsp;</p><p dir="RTL">CH &ndash; 8853 لاشين / سويسرا</p><p dir="RTL"><strong>الشركة المُصنِّعة </strong></p><p dir="RTL">أوكتافارما فارمازوتيكا بروداكشنز ذ.م.م</p><p dir="RTL">&nbsp;235- شارع أوبر لاير&nbsp;&nbsp;</p><p dir="RTL">A &ndash; 1100&nbsp;&nbsp; &nbsp;فيينا / النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Wilate 500, 500 IU VWF/500 IU FVIII, powder and solvent for solution for injection
Wilate 1000, 1000 IU VWF/1000 IU FVIII, powder and solvent for solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Wilate, produced from the plasma of human donors, is presented as a powder and solvent for solution for injection containing nominally 500 IU/1000 IU human von Willebrand factor (VWF) and human coagulation factor VIII (FVIII) per vial. 
The product contains approximately 100 IU/ml human von Willebrand factor when reconstituted with 5 ml/10 ml Water for Injections with 0.1 % Polysorbat 80.
The specific activity of Wilate is  67 IU VWF:RCo/mg protein.
The VWF potency (IU) is measured according to ristocetin cofactor activity (VWF:RCo) compared to the International Standard for von Willebrand Factor Concentrate (WHO).
The product contains approximately 100 IU/ml human coagulation factor VIII when reconstituted with 5 ml/10 ml Water for Injections with 0.1% Polysorbate 80.
The FVIII potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The specific activity of Wilate is  67 IU FVIII:C/mg protein. 
For  the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection. 
Freeze-dried powder: white or pale yellow powder or crumbly solid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Von Willebrand disease (VWD)</u></p><p>Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.</p><p><u>Haemophilia A</u></p><p>Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be under the supervision of a physician experienced in the treatment of coagulation disorders. The product is of single use and the full content of the vial should be administered. In case any content remains, it should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><u>Von Willebrand disease (VWD)</u></p><p>The ratio between VWF:RCo and FVIII:C is 1:1. Generally, 1 IU/kg BW VWF:RCo and FVIII:C raises the plasma level by 1.5-2% of normal activity for the respective protein. Usually, about 20 to 50 IU Wilate/kg BW are necessary to achieve adequate haemostasis. This will raise the VWF:RCo and FVIII:C in the patients by approx. 30 to 100%.</p><p>An initial dose of 50 to 80 IU Wilate/kg BW may be required, especially in patients with VWD type 3, where the maintenance of adequate plasma levels may require higher doses than in other types of VWD.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There are insufficient data to recommend the use of Wilate in children less than 6 years old.</p><p>&nbsp;</p><p><em>Prevention of haemorrhage in case of surgery or severe trauma:</em></p><p>For prevention of bleeding in case of surgery, Wilate should be given 1-2 hours before start of the surgical procedure. Levels of VWF:RCo of &sup3; 60 IU/dl (&sup3; 60%) and FVIII:C levels of &sup3; 40 IU/dl (&sup3; 40%) should be achieved.</p><p>An appropriate dose should be re-administered every 12-24 hours of treatment. The dose and duration of the treatment depend on the clinical status of the patient, the type and severity of bleeding, and both VWF:RCo and FVIII:C levels.</p><p>In patients receiving FVIII-containing VWF products, plasma levels of FVIII:C should be monitored to reveal sustained excessive FVIII:C plasma levels, which may increase the risk of thrombotic events, particularly in patients with known clinical or laboratory risk factors. In case excessive FVIII:C plasma levels are observed, reduced doses and/or prolongation of the dose interval or the use of VWF product containing a low level of FVIII should be considered.</p><p>&nbsp;</p><p><em>Prophylaxis:</em></p><p>For long term prophylaxis against bleeds in VWD patients, doses of 20-40 IU/kg bodyweight should be administered 2 or 3 times per week. In some cases, such as in patients with gastrointestinal bleeds, higher doses may be necessary.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Haemophilia A</u></p><p>The dose and duration of the substitution therapy depend on the severity of the FVIII deficiency, on the location and extent of the bleeding and on the patient&#39;s clinical condition.</p><p>The number of units of FVIII administered is expressed in International Units (IU), which are related to the current WHO standard for FVIII products. FVIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in IU (relative to an International Standard for FVIII in plasma).</p><p>One IU of FVIII activity is equivalent to that quantity of FVIII in one ml of normal human plasma.</p><p>&nbsp;</p><p><em>On demand treatment:</em></p><p>The calculation of the required dose of FVIII is based on the empirical finding that 1 IU FVIII:C/kg BW raises the plasma level by 1.5-2% of normal activity. The required dose is determined using the following formula:</p><p>Required IU = BW (kg) x desired FVIII rise (%) (IU/dl) x 0.5 IU/kg</p><p>The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case. In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (in % of normal or IU/dl) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery.</p><p>&nbsp;</p><p>Treatment scheme for Haemorrhages and Surgery</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>Degree of haemorrhage/<br />Type of surgical procedure</strong></p></td><td><p><strong>FVIII level<br />required (%)</strong></p><p><strong>(IU/dl)</strong></p></td><td><p><strong>Frequency of Doses<br />(hours)/Duration of Therapy (days)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Haemorrhage</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Early haemarthrosis, muscle bleeding or oral bleeding</p></td><td style="vertical-align:top"><p>20 &ndash; 40</p></td><td style="vertical-align:top"><p>Repeat every 12 to 24 hours. At least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.</p></td></tr><tr><td style="vertical-align:top"><p>More extensive haemarthrosis, muscle bleeding or haematoma</p></td><td style="vertical-align:top"><p>30 &ndash; 60</p></td><td style="vertical-align:top"><p>Repeat infusion every 12 to 24 hours for 3 to 4 days or more until pain and disability are resolved.</p></td></tr><tr><td style="vertical-align:top"><p>Life threatening haemorrhages</p></td><td style="vertical-align:top"><p>60 &ndash; 100</p></td><td style="vertical-align:top"><p>Repeat infusion every 8 to 24 hours until threat is resolved.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Surgery</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Minor</em><br />including tooth extraction</p></td><td style="vertical-align:top"><p>30 &ndash; 60</p></td><td style="vertical-align:top"><p>Every 24 hours, at least 1 day, until healing is achieved.</p></td></tr><tr><td style="vertical-align:top"><p><em>Major</em></p></td><td style="vertical-align:top"><p>80 &ndash; 100<br /><br /><br />(pre- and postoperative)</p></td><td style="vertical-align:top"><p>Repeat infusion every 8 to 24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a FVIII activity of 30% to 60% (IU/dl).</p></td></tr></tbody></table><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Prophylaxis:</em></p><p>For long-term prophylaxis against bleedings in patients with severe haemophilia A, doses of 20 to 40 IU Wilate/kg BW should be given at intervals of 2 to 3 days. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.</p><p>&nbsp;</p><p><em>Continuous infusion:</em></p><p>Prior to surgery, a pharmacokinetic analysis should be performed to obtain an estimate of clearance. The initial infusion rate can be calculated as follows:</p><p><strong>Infusion rate (IU/kg/h) = clearance (mL/kg/h) x desired steady state level (IU/mL)</strong></p><p>After the initial 24 hours of continuous infusion, the clearance should be calculated again every day using the steady state equation with the measured level and the known rate of infusion.</p><p>During the course of treatment, appropriate determination of FVIII:C levels is advised to guide the dose to be administered and the frequency of repeated infusions. In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (FVIII:C) is indispensable. Individual patients may vary in their response to FVIII treatment, achieving different half-lives and recoveries.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Previously untreated patients</em></p><p>Currently available data are described in section 4.8.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There are insufficient data to recommend the use of Wilate in haemophilia A in children less than 6 years old.</p><p><strong>Method of administration</strong></p><p>Intravenous use.</p><p>The injection or infusion rate should not exceed 2-3 ml per minute.</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with any intravenous infusion of a plasma-derived protein product, allergic type hypersensitivity reactions are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.</p><p>Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If allergic symptoms occur, patients should discontinue the administration immediately and contact their physician.</p><p>In case of shock, the current medical standards for treatment of shock should be implemented.</p><p>Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.</p><p>The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and for the non-enveloped hepatitis A virus. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.</p><p>Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia).</p><p>It is strongly recommended that every time that Wilate is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.</p><p>Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of human plasma-derived VWF/FVIII concentrates.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Von Willebrand disease (VWD)</u></p><p>When using a FVIII-containing VWF product, the treating physician should be aware that continued treatment may cause an excessive rise in FVIII:C. In patients receiving FVIII-containing VWF products, plasma levels of FVIII:C should be monitored to avoid sustained excessive FVIII:C plasma levels, which may increase the risk of thrombotic events.</p><p>There is a risk of occurrence of thrombotic events when using FVIII-containing VWF products, particularly in patients with known clinical or laboratory risk factors. Therefore, patients at risk must be monitored for early signs of thrombosis. Prophylaxis against venous thromboembolism should be instituted, according to the current recommendations.</p><p>Patients with VWD, especially type 3 patients, may develop neutralising antibodies (inhibitors) to VWF. If the expected VWF:RCo activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an appropriate assay should be performed to determine if a VWF inhibitor is present. In patients with high levels of inhibitor, VWF therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of patients with haemostatic disorders.</p><p><u>&nbsp;</u></p><p><u>Haemophilia A</u></p><p><u>Hypersensitivity </u></p><p>Allergic type hypersensitivity reactions are possible with Wilate. The product contains traces of human proteins other than FVIII. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.</p><p>In case of shock, standard medical treatment for shock should be implemented.</p><p><u>&nbsp;</u></p><p><u>Inhibitors </u></p><p>The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the FVIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay. The risk of developing inhibitors is correlated to the exposure to FVIII, this risk being highest within the first 20 exposure days. Rarely, inhibitors may develop after the first 100 exposure days.</p><p>Cases of recurrent inhibitor (low titre) have been observed after switching from one FVIII product to another in previously treated patients with more than 100 exposure days who have a previous history of inhibitor development. Therefore, it is recommended to monitor all patients carefully for inhibitor occurrence following any product switch.</p><p>In general, all patients treated with coagulation FVIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests. If the expected FVIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for FVIII inhibitor presence should be performed. In patients with high levels of inhibitor, FVIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of haemophilia and FVIII inhibitors.</p><p>&nbsp;</p><p>This medicinal product contains up to 2.55 mmol sodium (58.7 mg) per vial for 500 IU VWF and FVIII/vial and up to 5.1 mmol sodium (117.3 mg) per vial for 1000 IU VWF and FVIII/vial. To be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions with other medicinal products are known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal reproduction studies have not been conducted with VWF/FVIII.</p><p><u>Von Willebrand disease (VWD)</u></p><p>Experience in the treatment of pregnant or lactating women is not available.</p><p>Wilate should be administered to pregnant or lactating VWF deficient women only if clearly indicated, taking into consideration that delivery confers an increased risk of haemorrhagic events in these patients.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Haemophilia A</u></p><p>Based on the rare occurrence of haemophilia A in women, experience regarding the treatment during pregnancy and breastfeeding is not available. Therefore, Wilate should be used during pregnancy and lactation only if clearly indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Wilate has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>To report any side effect(s):</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>o&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><u>Summary of the safety profile</u></p><p>Hypersensitivity or allergic reactions (which may include angiooedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely, and may in some cases progress to severe anaphylaxis (including shock). In rare occasions, fever has been observed.</p><p>&nbsp;</p><p><u>Von Willebrand disease (VWD)</u></p><p>Patients with VWD, especially type 3 patients, may very rarely develop neutralising antibodies to VWF. If such inhibitors occur, the condition will manifest itself as an inadequate clinical response. Such antibodies occur in close association with anaphylactic reactions. Therefore, patients experiencing anaphylactic reaction should be evaluated for the presence of an inhibitor.</p><p>In all such cases, it is recommended that a specialised haemophilia centre be contacted.</p><p>No cases of inhibitors for von Willebrand factor have been reported from clinical studies or from post marketing experience for Wilate so far.</p><p>There is a risk of occurrence of thrombotic events, particularly in patients with known clinical or laboratory risk factors. Prophylaxis against venous thromboembolism should be instituted, according to the current recommendations.</p><p>In patients receiving FVIII-containing VWF products sustained excessive FVIII:C plasma levels may increase the risk of thrombotic events.</p><p><u>&nbsp;</u></p><p><u>Haemophilia A</u></p><p>Patients with haemophilia A may develop neutralising antibodies (inhibitors) to FVIII. If such inhibitors occur, the condition will manifest as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.</p><p>The experience with Wilate in previously untreated patients (PUPs) is limited. In a clinical trial involving 24 PUPs with a minimum of 50 exposure days treated with Wilate, only three patients with a persistent and clinically manifest inhibitor above 5 BU/ml could be detected. Three patients developed low titre, transient inhibitors without any clinical manifestations, and two patients had a low titre inhibitor on a single occasion with no follow-up result.</p><p>See also section 4.2. There were no inhibitor developments observed in previously treated patients.</p><p>&nbsp;</p><p>For safety information with respect to transmissible agents, see section 4.4</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).</p><p>Frequencies have been evaluated according to the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>System Organ Class</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Rare</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactic shock</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>FVIII inhibitors</p></td><td style="vertical-align:top"><p>VWF inhibitors</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>Description of selected adverse reactions</p><p>For description of selected adverse reactions, see section 4.4</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No symptoms of overdose with human VWF or FVIII have been reported. Thromboembolic events may occur in case of major overdose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:<u> Antihaemorrhagics: blood coagulation factors </u></p><p>Von Willebrand factor and coagulation factor VIII in combination</p><p>ATC Code: B02BD06</p><p><u>&nbsp;</u></p><p><u>Von Willebrand disease (VWD)</u></p><p>The VWF (from the concentrate) is a normal constituent of the human plasma and behaves in the same way as endogenous VWF.</p><p>Administration of VWF allows correction of the haemostatic abnormalities exhibited in patients who suffer from VWF deficiency (VWD) at two levels:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; VWF re-establishes platelet adhesion to the vascular sub-endothelium at the site of vascular damage (as it binds both to the vascular sub-endothelium and to the platelet membrane), providing primary haemostasis as shown by the shortening of the bleeding time. This effect occurs immediately and is known to depend to a large extent to the level of polymerisation of the protein;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; VWF produces delayed correction of the associated FVIII deficiency. Administered intravenously, VWF binds endogenous FVIII (which is produced normally by the patient), and by stabilising this factor, avoids its rapid degradation.<br />Because of this, administration of pure VWF (VWF product with a low FVIII level) restores the FVIII:C level to normal as a secondary effect <u>after first infusion.</u><br />Administration of a FVIII-containing VWF preparation restores the FVIII:C level to normal immediately<u> after first infusion.</u></p><p>In addition to its role as a FVIII-protecting protein, VWF mediates platelet adhesion to sites of vascular injury and plays a role in platelet aggregation.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Haemophilia A</u></p><p>The FVIII/VWF complex consists of two molecules (FVIII and VWF) with different physiological functions. When infused into a haemophilia patient, FVIII binds to VWF in the patient&acute;s circulation. Activated FVIII (FVIIIa) acts as a cofactor for activated factor IX (FIXa), accelerating the conversion of factor X to activated factor X (FXa). FXa converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed.</p><p>Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of FVIII:C and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of FVIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Von Willebrand disease (VWD)</u></p><p>VWF (from the concentrate) is a normal constituent of the human plasma and acts like the endogenous VWF.<strong><em> </em></strong></p><p>Based on meta-analysis of three pharmacokinetic studies involving 24 evaluable patients with all VWD types, the following results were observed.</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:bottom"><p><strong>All VWD types</strong></p></td><td colspan="5" style="vertical-align:bottom"><p><strong>VWD type 1</strong></p></td><td colspan="5" style="vertical-align:bottom"><p><strong>VWD type 2</strong></p></td><td colspan="5" style="vertical-align:bottom"><p><strong>VWD type 3</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Parameter</p></td><td style="vertical-align:bottom"><p><strong>N</strong></p></td><td style="vertical-align:bottom"><p>Mean</p></td><td style="vertical-align:bottom"><p>SD</p></td><td style="vertical-align:bottom"><p>Min.</p></td><td style="vertical-align:bottom"><p>Max.</p></td><td style="vertical-align:bottom"><p><strong>N</strong></p></td><td style="vertical-align:bottom"><p>Mean</p></td><td style="vertical-align:bottom"><p>SD</p></td><td style="vertical-align:bottom"><p>Min.</p></td><td style="vertical-align:bottom"><p>Max.</p></td><td style="vertical-align:bottom"><p><strong>N</strong></p></td><td style="vertical-align:bottom"><p>Mean</p></td><td style="vertical-align:bottom"><p>SD</p></td><td style="vertical-align:bottom"><p>Min.</p></td><td style="vertical-align:bottom"><p>Max.</p></td><td style="vertical-align:bottom"><p><strong>N</strong></p></td><td style="vertical-align:bottom"><p>Mean</p></td><td style="vertical-align:bottom"><p>SD</p></td><td style="vertical-align:bottom"><p>Min.</p></td><td style="vertical-align:bottom"><p>Max.</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Recovery (%/IU/kg)</p></td><td style="vertical-align:top"><p><strong>24</strong></p></td><td style="vertical-align:top"><p>1.56</p></td><td style="vertical-align:top"><p>0.48</p></td><td style="vertical-align:top"><p>0.90</p></td><td style="vertical-align:top"><p>2.93</p></td><td style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p>1.19</p></td><td style="vertical-align:top"><p>0.07</p></td><td style="vertical-align:top"><p>1.14</p></td><td style="vertical-align:top"><p>1.24</p></td><td style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p>1.83</p></td><td style="vertical-align:top"><p>0.86</p></td><td style="vertical-align:top"><p>0.98</p></td><td style="vertical-align:top"><p>2.93</p></td><td style="vertical-align:top"><p><strong>17</strong></p></td><td style="vertical-align:top"><p>1.52</p></td><td style="vertical-align:top"><p>0.32</p></td><td style="vertical-align:top"><p>0.90</p></td><td style="vertical-align:top"><p>2.24</p></td></tr><tr><td style="vertical-align:top"><p>AUC (0-inf) (h*%)</p></td><td style="vertical-align:top"><p><strong>23</strong></p></td><td style="vertical-align:top"><p>1981</p></td><td style="vertical-align:top"><p>960</p></td><td style="vertical-align:top"><p>593</p></td><td style="vertical-align:top"><p>4831</p></td><td style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p>2062</p></td><td style="vertical-align:top"><p>510</p></td><td style="vertical-align:top"><p>1701</p></td><td style="vertical-align:top"><p>2423</p></td><td style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p>2971</p></td><td style="vertical-align:top"><p>1383</p></td><td style="vertical-align:top"><p>1511</p></td><td style="vertical-align:top"><p>4831</p></td><td style="vertical-align:top"><p><strong>16</strong></p></td><td style="vertical-align:top"><p>1662</p></td><td style="vertical-align:top"><p>622</p></td><td style="vertical-align:top"><p>593</p></td><td style="vertical-align:top"><p>2606</p></td></tr><tr><td style="vertical-align:top"><p>T 1/2 (h)</p></td><td style="vertical-align:top"><p><strong>24</strong></p></td><td style="vertical-align:top"><p>23.3</p></td><td style="vertical-align:top"><p>12.6</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>58.4</p></td><td style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p>39.7</p></td><td style="vertical-align:top"><p>18.3</p></td><td style="vertical-align:top"><p>26.7</p></td><td style="vertical-align:top"><p>52.7</p></td><td style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p>34.9</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>17.5</p></td><td style="vertical-align:top"><p>58.4</p></td><td style="vertical-align:top"><p><strong>17</strong></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>6.2</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>30.5</p></td></tr><tr><td style="vertical-align:top"><p>MRT (h)</p></td><td style="vertical-align:top"><p><strong>24</strong></p></td><td style="vertical-align:top"><p>33.1</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>10.1</p></td><td style="vertical-align:top"><p>89.7</p></td><td style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p>53.6</p></td><td style="vertical-align:top"><p>25.9</p></td><td style="vertical-align:top"><p>35.3</p></td><td style="vertical-align:top"><p>71.9</p></td><td style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p>53.5</p></td><td style="vertical-align:top"><p>24.6</p></td><td style="vertical-align:top"><p>27.8</p></td><td style="vertical-align:top"><p>89.7</p></td><td style="vertical-align:top"><p><strong>17</strong></p></td><td style="vertical-align:top"><p>24.7</p></td><td style="vertical-align:top"><p>8.5</p></td><td style="vertical-align:top"><p>10.1</p></td><td style="vertical-align:top"><p>37.7</p></td></tr><tr><td style="vertical-align:top"><p>Clearance (mL/h/kg)</p></td><td style="vertical-align:top"><p><strong>24</strong></p></td><td style="vertical-align:top"><p>3.29</p></td><td style="vertical-align:top"><p>1.67</p></td><td style="vertical-align:top"><p>0.91</p></td><td style="vertical-align:top"><p>7.41</p></td><td style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p>2.66</p></td><td style="vertical-align:top"><p>0.85</p></td><td style="vertical-align:top"><p>2.06</p></td><td style="vertical-align:top"><p>3.27</p></td><td style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p>1.95</p></td><td style="vertical-align:top"><p>1.02</p></td><td style="vertical-align:top"><p>0.91</p></td><td style="vertical-align:top"><p>3.31</p></td><td style="vertical-align:top"><p><strong>17</strong></p></td><td style="vertical-align:top"><p>3.76</p></td><td style="vertical-align:top"><p>1.69</p></td><td style="vertical-align:top"><p>1.83</p></td><td style="vertical-align:top"><p>7.41</p></td></tr></tbody></table><p>&nbsp;</p><p>Key: AUC = area under the curve; MRT = mean residence time</p><p><u>&nbsp;</u></p><p><u>Haemophilia A</u></p><p>FVIII (from the concentrate) is a normal constituent of the human plasma and acts like the endogenous FVIII. After injection of the product, approximately two thirds to three quarters of the FVIII remain in the circulation. The level of FVIII:C reached in the plasma should be between 80-120% of the predicted FVIII:C.</p><p>FVIII:C decreases by a two-phase exponential decay. In the initial phase, distribution between the intravascular and other compartments (body fluids) occurs with a half-life of elimination from the plasma of 3 to 6 hours. In the subsequent slower phase, the half-life varies between 8 to 18 hours, with an average of 15 hours. This corresponds to the true biological half-life.</p><p>The following results were observed in one clinical study in 12 patients (chromogenic assay, double measurement):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter</p></td><td colspan="2" style="vertical-align:top"><p>Baseline visit</p></td><td colspan="2" style="vertical-align:top"><p>6-month visit</p></td></tr><tr><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>SD</p></td><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>SD</p></td></tr><tr><td style="vertical-align:top"><p>Recovery<br />%/IU/kg</p></td><td style="vertical-align:top"><p>FVIII:C 2.27</p></td><td style="vertical-align:top"><p>1.20</p></td><td style="vertical-align:top"><p>FVIII:C 2.26</p></td><td style="vertical-align:top"><p>1.19</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>norm</sub><br />% * h/IU/kg</p></td><td style="vertical-align:top"><p>FVIII:C 31.3</p></td><td style="vertical-align:top"><p>7.31</p></td><td style="vertical-align:top"><p>FVIII:C 33.8</p></td><td style="vertical-align:top"><p>10.9</p></td></tr><tr><td style="vertical-align:top"><p>Half-life (h)</p></td><td style="vertical-align:top"><p>FVIII:C 11.2</p></td><td style="vertical-align:top"><p>2.85</p></td><td style="vertical-align:top"><p>FVIII:C 11.8</p></td><td style="vertical-align:top"><p>3.37</p></td></tr><tr><td style="vertical-align:top"><p>MRT (h)</p></td><td style="vertical-align:top"><p>FVIII:C 15.3</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>FVIII:C 16.3</p></td><td style="vertical-align:top"><p>4.6</p></td></tr><tr><td style="vertical-align:top"><p>Clearance<br />mL/h/kg</p></td><td style="vertical-align:top"><p>FVIII:C<br />3.37</p></td><td style="vertical-align:top"><p>0.86</p></td><td style="vertical-align:top"><p>FVIII:C<br />3.24</p></td><td style="vertical-align:top"><p>1.04</p></td></tr></tbody></table><p>&nbsp;</p><p>Key: AUC = area under the curve; MRT = mean residence time; SD = standard deviation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VWF and FVIII in Wilate are normal constituents of the human plasma and act like the endogenous VWF/FVIII.</p><p>Conventional safety testing of these compounds in laboratory animals would not add useful information to the existing clinical experience and therefore is not required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder: Sodium chloride, Glycine, Sucrose, Sodium citrate and Calcium chloride</p><p>Solvent: Water for injections with 0.1 % Polysorbate 80</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, Wilate must not be mixed with other medicinal products or administered simultaneously with other intravenous preparation in the same infusion set.</p><p>Only the provided injection/infusion sets should be used because treatment failure can occur as a consequence of FVIII/VWF adsorption to the internal surfaces of some infusion equipment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years. 
Use the solution immediately after reconstitution.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store powder and solvent vial in a refrigerator (2-8&deg;C). Keep the vials in the outer carton in order to protect from light. Do not freeze.</p><p>Within the indicated expiry date storage for up to 6 months at room temperature (max. +25&deg;C) is permitted. The shelf-life expires after the storage at room temperature (max. +25&deg;C). The new shelf-life has to be noted on the outer carton by the patient. The reconstituted solution should be used on one occasion only. Any solution remaining should be discarded.</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Package sizes:</p><p>Wilate 500, 500&nbsp;IU VWF and 500 IU FVIII</p><p>1 package contains:</p><p>1 vial with Powder, type I glass, closed with a stopper (bromobutyl rubber) and sealed with a flip off cap</p><p>1 vial with Solvent (5 ml Water for Injections with 0.1% Polysorbate 80), type I glass, closed with a stopper (halobutyl rubber) and sealed with a flip off cap</p><p>1 equipment pack with the medical devices (1 disposable syringe, 1 transfer set (1&nbsp;double-ended needle and 1 filter needle), 1 infusion set)</p><p>2 alcohol swabs</p><p>&nbsp;</p><p>Wilate 1000, 1000&nbsp;IU VWF and 1000 IU FVIII</p><p>1 package contains:</p><p>1 vial with Powder, type I glass, closed with a stopper (bromobutyl rubber) and sealed with a flip off cap</p><p>1 vial with Solvent (10 ml Water for Injections with 0.1% Polysorbate 80), type I glass, closed with a stopper (halobutyl rubber) and sealed with a flip off cap</p><p>1 equipment pack with the medical devices (1 disposable syringe, 1 transfer set &nbsp;(1&nbsp;double-ended needle and 1 filter needle), 1 infusion set)</p><p>2 alcohol swabs</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Instructions for reconstitution:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warm the Powder and Solvent in the closed vials up to room temperature. This temperature should be maintained during reconstitution. If a water bath is used for warming, care must be taken to avoid water coming into contact with the rubber stoppers (latex-free) or the caps of the vials. The temperature of the water bath should not exceed +37&deg;C.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the caps from the powder vial and the solvent vial and clean the rubber stoppers with an alcohol swab.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the protective cover from the short end of the double-ended needle, making sure not to touch the exposed tip of the needle.<br />Then perforate the centre of the solvent vial rubber stopper with the vertically held needle. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />In order to withdraw the fluid from the solvent vial completely, the needle must be introduced into the rubber stopper in such a way that it just penetrates the stopper and is visible in the vial.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the protective cover from the other, long end of the double-ended needle, making sure not to touch the exposed tip of the needle. &nbsp;<br />Hold the solvent vial upside-down above the upright powder vial and quickly perforate the centre of the concentrate vial rubber stopper with the needle. The vacuum inside the concentrate vial draws in the solvent.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the double-ended needle with the empty solvent vial from the powder vial, then slowly rotate the vial until the concentrate is completely dissolved. Wilate dissolves quickly at room temperature to a clear solution.</p><p>The solution is clear to slightly opalescent. If the concentrate fails to dissolve completely or an aggregate is formed, the preparation must not be used.</p><p>Instructions for injection:</p><p>As a precautionary measure, the patients pulse rate should be measured before and during the FVIII injection. If a marked increase in the pulse rate occurs the injection speed must be reduced or the administration must be interrupted.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the powder has been reconstituted in the manner described above, remove the protective cover from the filter needle and perforate the rubber stopper of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />concentrate vial.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the cap of the filter needle and attach the syringe.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the vial with the attached syringe upside-down and draw the solution up into the syringe.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clean the intended injection site with an alcohol swab.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the filter needle from the syringe and attach the butterfly infusion needle to the syringe instead.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject the solution intravenously at a slow speed of 2-3 ml/minute.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OCTAPHARMA AG
Seidenstrasse 2
CH-8853 Lachen
Switzerland

Manufacturer
Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30/03/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>